What's Happening?
A recent KFF Health Tracking Poll reveals that approximately 12% of adults are currently using GLP-1 drugs, such as Ozempic and Wegovy, for weight loss or managing chronic conditions. The poll indicates a significant increase in usage over the past 18
months, despite concerns about the high costs of these medications. Women and adults aged 50-64 are more likely to use these drugs, while Medicare's lack of coverage for weight loss prescriptions contributes to lower usage among seniors. The poll also highlights that many users find these drugs difficult to afford, with cost being a primary reason for discontinuation.
Why It's Important?
The growing use of GLP-1 drugs reflects a broader trend in healthcare where individuals seek effective treatments for weight management and chronic conditions. However, the high cost of these medications poses a barrier to access, particularly for uninsured individuals and those with limited financial resources. The situation underscores the need for policy interventions to address drug pricing and improve insurance coverage. The poll's findings may influence future healthcare policies and discussions around prescription drug affordability.
